On July 3, 2020, the company's Chief Executive Officer of Anchiano Therapeutics Ltd. Dr. Frank Haluska sent a letter to the company's Chairman that the Board has considered and construes as notice of constructive resignation. The letter outlined Dr. Haluska’s belief that events have occurred that are sufficient to trigger his ability to resign for “Good Reason” under his employment agreement, and that he intends to resign as of August 8, 2020 assuming the “Good Reason” events are not cured within thirty (30) days. After discussion and advice from Company legal counsel, the Board has informed Dr. Haluska that it completely disagrees with the letter’s assertions regarding “Good Reason”. At the same time, the Board has concluded that based on the content and nature of Dr. Haluska’s letter, it is reasonable to treat the letter as a constructive resignation. As a result, the Board has resolved to relieve Dr. Haluska of his CEO duties effective immediately. In the letter, Dr. Haluska also confirms his intent to resign as a director of the Company. However, as of this date he has not submitted his formal resignation. Until a new CEO is identified and appointed the Board will handle all matters related to CEO duties.